New World Advisors LLC Sells 100 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

New World Advisors LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,553 shares of the medical equipment provider’s stock after selling 100 shares during the quarter. New World Advisors LLC’s holdings in Zimmer Biomet were worth $384,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. M&G Plc acquired a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $7,397,000. Gradient Investments LLC boosted its holdings in shares of Zimmer Biomet by 17.3% in the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock valued at $14,147,000 after purchasing an additional 19,224 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Zimmer Biomet by 7.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after buying an additional 15,548 shares in the last quarter. Swedbank AB acquired a new stake in Zimmer Biomet in the first quarter valued at about $2,740,000. Finally, Forsta AP Fonden grew its position in Zimmer Biomet by 95.1% in the first quarter. Forsta AP Fonden now owns 99,100 shares of the medical equipment provider’s stock valued at $13,079,000 after acquiring an additional 48,300 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 1.6 %

Shares of NYSE:ZBH traded down $1.65 during midday trading on Friday, reaching $102.35. The company’s stock had a trading volume of 1,398,183 shares, compared to its average volume of 1,474,492. The firm has a 50 day moving average price of $107.61 and a two-hundred day moving average price of $111.47. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The firm has a market capitalization of $21.06 billion, a price-to-earnings ratio of 22.15, a PEG ratio of 1.92 and a beta of 1.02. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the firm posted $1.82 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.94%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ZBH shares. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. Evercore ISI decreased their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Royal Bank of Canada dropped their price target on Zimmer Biomet from $130.00 to $120.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. TD Cowen reduced their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Finally, Robert W. Baird dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $123.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.